We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Maelor | LSE:MLR | London | Ordinary Share | GB00B2QBY649 | ORD 70P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 100.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:2174X
Maelor PLC
20 January 2006
Geoff McMillan appointed as Non-Executive Chairman of Maelor PLC
20 January 2006: Maelor Pharmaceuticals, the specialist healthcare products
company, today announces the retirement of its Chairman, Alastair Macpherson
(61). Geoff McMillan, currently a Non-Executive Director of Maelor, will be
appointed as Chairman.
Tim Wright, Chief Executive Officer of Maelor commented:
"On behalf of the board I would like to express our thanks and appreciation to
Alastair for his hard work and commitment to the company over the last seven and
a half years. We wish him well with his future projects. I very much look
forward to working with Geoff as we complete our strategic review and implement
plans to grow and develop Maelor."
Enquiries:
Maelor plc
Tim Wright, CEO
Tel: 01978 810153
Financial Dynamics
Ben Atwell/John Gilbert
Tel: 020 7831 3113
Notes to Editors:
About Maelor
Maelor plc is an AIM-listed specialist healthcare products company, which
operates on a virtual basis, outsourcing both product development and
manufacturing. The company has several products on the market including OptiFlo,
ContiSol and Volplex.
About Geoff McMillan
Henry Geoffrey (Geoff) McMillan, aged 49, is currently a non-executive director
of Maelor Plc and Galapagos NV, with over twenty years' experience within the
pharma and biopharma sectors. He joined BioFocus as COO in 2002 and was CEO of
the company from May 2003 to October 2005. Prior to this, Mr. McMillan was with
Elan where he was instrumental in the development of Elan internationally. In
1993, he joined the board of Xenova Group Plc as Commercial Director. Before
this, he was Global Head of Business Development and Planning and a member of
Roche's Pharmaceutical Division board. At the start of his career he held
several sales and marketing positions at Smith and Nephew.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAURVWRNKRAURR
1 Year Maelor Chart |
1 Month Maelor Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
